Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Advanced Nanotech's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was NT$-102.1 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-220.6 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Taiwan Advanced Nanotech's annualizedROC % for the quarter that ended in Dec. 2025 was -44.76%.
Taiwan Advanced Nanotech's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -44.41%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Taiwan Advanced Nanotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -547.99%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Taiwan Advanced Nanotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advanced Nanotech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiwan Advanced Nanotech's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-220.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advanced Nanotech (ROCO:6797) has a EBIT of NT$-220.6 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Taiwan Advanced Nanotech.
Is Taiwan Advanced Nanotech's EBIT too high?
Taiwan Advanced Nanotech's current EBIT is NT$-220.6 Mil. Overall, Taiwan Advanced Nanotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's EBIT compare to ABT and SYK?
Taiwan Advanced Nanotech's EBIT of NT$-220.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Taiwan Advanced Nanotech. Taiwan Advanced Nanotech's current EBIT is NT$-220.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.40, compared to a current price of NT$13.20 — trading 1.5% below its estimated fair value. The current EBIT is NT$-220.6 Mil. Taiwan Advanced Nanotech's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current EBIT is NT$-220.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued.
The current stock price of NT$13.20 is trading 1.5% below its estimated GF Value™ of NT$13.40.
GuruFocus considers Taiwan Advanced Nanotech to be Fairly Valued.
Key valuation signals for ROCO:6797:
EBIT: NT$-220.6 Mil
GF Value™: NT$13.40 vs. price of NT$13.20 (1.5% below fair value)
No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
59GF Score
Get the complete analysis for ROCO:6797
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6797 has been successfully added to your 
